Telix Pharmaceuticals (TLX:ASX) is a clinical-stage biopharmaceutical company developing a portfolio of diagnostic and therapeutic radiopharmaceuticals to address significant unmet needs in oncology and rare diseases. Telix's radiopharmaceuticals are designed to target and treat cancer cells or other diseased cells with precision, while minimising damage to healthy tissue. Telix's objectives are to advance its portfolio of radiopharmaceutical products through clinical development and into commercialisation, to become a leading global radiopharmaceutical company, and to improve the lives of patients with cancer and rare diseases.